MarginsXMarginsX
Home › Canada › TSXV stocks › MPH

Medicure Inc. (TSXV: MPH)

MPH trades on the TSX Venture Exchange in Life Sciences, headquartered in Manitoba. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.

Close · November 13, 2026
C$3.70
-7.50% on the day
Market cap (C$)
C$44.9M
TMX list, October 31, 2026
Market cap (US$)
US$31.5M
Nano cap at 1.4257 C$/US$
1-year return
+186.8%
+224.6% year to date

Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of October 31, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for MPH.V, last bar 2026-11-13, computed by MarginsX. Website: sociallinks: 20-F text ("our website").

Profile

FieldValue
TickerMPH on the TSX Venture Exchange
Yahoo symbolMPH.V
SectorLife Sciences
HeadquartersManitoba
Listed2010-03-29
Listing typeTSX Comedown
Shares outstanding10,436,313
Also listed onNo interlisting on the TMX list
Index membershipNot in an S&P/TSX index per the TMX list
SEC CIK0001133519
Websitewww.medicure.com

Returns

WindowReturn
1 day-7.5%
1 week-1.3%
1 month0.0%
3 months+172.1%
6 months+221.7%
Year to date+224.6%
1 year+186.8%
From 52-week high-16.7%
52-week rangeC$0.9000 to C$4.44

Links

SEDAR+ is linked for searching only; nothing on this page is taken from it.

Recent Canadian filings by type

46 documents in 6 types. Each title links to the document at its source.

Interim financial statements (6)

DocumentTypeFiled
FINANCIAL STATEMENTSInterim financial statements (6-K)2026-08-19
FINANCIAL STATEMENTS
Period 2026-03-31
Interim financial statements (6-K)2026-05-21
FINANCIAL STATEMENTS
Period 2025-09-30
Interim financial statements (6-K)2025-11-19
FINANCIAL STATEMENTS
Period 2025-06-30
Interim financial statements (6-K)2025-08-21

MD&A (3)

DocumentTypeFiled
Q2 MD&AMD&A (interim) (6-K)2026-08-19
MANAGEMENT'S DISCUSSION AND ANALYSIS
Period 2025-09-30
MD&A (interim) (6-K)2025-11-19
Q3 MD&AMD&A (interim) (6-K)2024-11-26

News release (17)

DocumentTypeFiled
PRESS RELEASENews release (6-K)2026-08-19
PRESS RELEASENews release (6-K)2026-05-21
PRESS RELEASENews release (6-K)2026-05-21
PRESS RELEASENews release (6-K)2026-04-24

Annual report (2)

DocumentTypeFiled
FORM 20-F
Period 2025-12-31
Annual report (20-F) (20-F)2026-04-24
FORM 20-F
Period 2024-12-31
Annual report (20-F) (20-F)2025-04-25

Certification (10)

DocumentTypeFiled
CEO CertificationCertification (52-109) (6-K)2026-08-19
CFO CertificationCertification (52-109) (6-K)2026-08-19
CERTIFICATION OF CEO
Period 2024-12-31
Certification (52-109) (20-F)2025-04-25
CERTIFICATION OF CFO
Period 2024-12-31
Certification (52-109) (20-F)2025-04-25

Other (8)

DocumentTypeFiled
CONSENT
Period 2025-12-31
Consent (20-F)2026-04-24
CONSENTS
Period 2024-12-31
Consent (20-F)2025-04-25
INSIDER TRADING POLICY
Period 2025-12-31
Material contract / governance (20-F)2026-04-24
CLAWBACK POLICY
Period 2025-12-31
Material contract / governance (20-F)2026-04-24

Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.

Trading halts

No CIRO halt notices for this company in our data.

Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.

Upcoming events

No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.

Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.

Peers in Life Sciences

TickerCompanyExchangeMarket cap (C$)1 month1 year
NLHNova Leap Health Corp.TSXVC$43.7M+8.9%+53.1%
NRXNurExone Biologic Inc.TSXVC$46.3M-22.5%-33.6%
TLTTheralase Technologies Inc.TSXVC$46.3M+5.6%-5.0%
TTIThiogenesis Therapeutics, Corp.TSXVC$43.4M+18.2%-7.1%
SHRXSharp Therapeutics Corp.TSXVC$43.3M0.0%-67.4%

The app has the price chart, every filing, private raises and the full peer set for MPH.

Open in the app